Tanning / Melanocortin

Melanotan II: What the Research Actually Shows

Last updated: April 2026

By Scott Williams·Firefighter/Paramedic · 25+ Years

Melanotan II is one of the more complicated peptides to write about honestly.

The mechanism is genuinely interesting. The original idea made sense: if researchers could create a tan with less UV exposure, maybe they could reduce sun damage and lower skin-cancer risk. That was a serious research goal, not random internet peptide culture.

The work came out of the University of Arizona in the 1980s, where researchers were studying melanocortin biology and synthetic analogs of alpha-melanocyte-stimulating hormone. The goal was UV-independent tanning — or at least UV-reduced tanning — as a possible skin cancer prevention strategy.

That is the interesting side.

The complicated side is that Melanotan II does not only hit the tanning pathway.

It activates multiple melanocortin receptors at once. That means the tanning effect, the sexual arousal effect, appetite suppression, blood pressure effects, nausea, flushing, and mole changes are all part of the same non-selective receptor story.

With some peptides, the safety concerns are mostly theoretical. With Melanotan II, several of the concerns are documented in the literature: mole changes, new moles, melanoma case reports, priapism, nausea, and other effects.

That does not mean every user develops a serious problem. It also does not mean the mechanism is fake.

It means this is the peptide where the interesting biology and the concerning safety record live in the same molecule.

Where I am stating a fact, I am citing it. Where I am sharing my read on the research, I am saying that out loud.

Verified Source

Ascension Peptides10mg

COA-verified · MZ Biolabs · US domestic

Use code BIOHACKING for 50% off your first order

Shop Melanotan II→

We only recommend vendors that pass our COA standard. How we vet →

What Melanotan II actually is

Melanotan II, often written as MT-II, is a synthetic analog of alpha-melanocyte-stimulating hormone, or alpha-MSH.

Alpha-MSH is part of the body's melanocortin system. That system influences pigmentation, appetite, sexual function, inflammation, and other biological pathways.

Melanotan II is a cyclic heptapeptide, meaning it is a seven-amino-acid cyclic peptide. The cyclic structure helped make it more potent and longer-lasting than the natural hormone signal it was based on.

The original research goal was tanning.

The idea was simple enough: stimulate melanin production without requiring the same level of ultraviolet exposure. More melanin could theoretically mean more natural photoprotection. Less UV exposure could theoretically mean less skin damage.

That is not a silly idea. It was a real scientific direction.

But Melanotan II itself never became an FDA-approved tanning drug.

One of the reasons is that MT-II was not selective enough. It activated multiple melanocortin receptors, and that produced effects beyond tanning.

The PT-141 / Bremelanotide connection

A related compound, bremelanotide, also known as PT-141, was developed from this melanocortin research path. Bremelanotide was engineered toward a more selective sexual-function target, especially involving MC4R activity. It eventually became Vyleesi, an FDA-approved drug for hypoactive sexual desire disorder in premenopausal women.

That connection is useful, but it needs to be framed carefully. Bremelanotide's approval validates that melanocortin receptor biology is real and clinically relevant. It does not validate Melanotan II's non-selective profile as safe or approved.

My read: the science behind Melanotan II is real. The problem is not that the molecule does nothing. The problem is that it does too many things at once.

How it's supposed to work

Melanotan II is a non-selective melanocortin receptor agonist.

That means it activates several melanocortin receptors, including:

MC1R — the tanning pathway

Activating MC1R increases melanin production in melanocytes. This is the effect most people are chasing when they use MT-II for tanning.

MC3R & MC4R — CNS effects

Involved in central nervous system effects, including appetite and sexual arousal pathways. This is why MT-II became known for spontaneous erections, libido effects, and appetite suppression.

MC4R — autonomic effects

Also tied to blood pressure and autonomic effects, which helps explain why blood pressure changes and flushing are part of the concern profile.

Plain English: Melanotan II hits multiple switches at once.

The tanning switch is one of them. The sexual arousal switch is another. Appetite suppression is another. Blood pressure effects are another. Nausea and flushing are part of the same broad receptor activity picture.

You do not get to pick only the tanning switch.

That non-selectivity is the core pharmacological issue.

The biology is fascinating. But fascinating is not the same as clean.

What the research shows

The human research on Melanotan II is real, but it is small and dated.

The foundational tanning study is Dorr et al. (1996). This was an early Phase 1 study looking at Melanotan II in healthy volunteers. The sample size was extremely small — some protocols involved only three healthy male volunteers. Low-dose subcutaneous MT-II increased pigmentation, but side effects were also documented, including nausea, fatigue, and spontaneous erections.

That is the basic MT-II story in miniature: Yes, the tanning effect showed up. So did the off-target effects.

Wessells et al. (1998) studied MT-II in men with psychogenic erectile dysfunction. In one small cohort, 8 of 10 men developed clinically apparent erections. Related dose-response work reported increased sexual desire after 13 of 19 MT-II doses compared with 4 of 21 placebo doses.

That is real pharmacodynamic activity. But again, the studies were small and early-stage. They were not large long-term safety trials.

The human evidence tells us MT-II can affect pigmentation and sexual function pathways. It does not give us a clean long-term safety profile.

My read: Melanotan II clearly does something. The problem is not lack of activity. The problem is the activity is broad, messy, and tied to safety signals that are hard to ignore.

What the community uses it for

Community-reported uses — not endorsements.

Melanotan II is mostly used in the community for tanning. The common goal is darker pigmentation with less sun exposure, faster tanning, or less burning.

Key point: UV exposure is still usually required for tanning to develop. MT-II may stimulate melanin production, but the visible tanning process still generally involves UV exposure. Some people may still increase UV exposure because they want to get darker faster. That changes the risk picture.

Melanotan II is also used for sexual arousal effects. Sometimes people see that as a benefit. Sometimes it is unwanted. Appetite suppression is another reported use, though MT-II is not an approved weight-management drug.

Common community-reported dosing often clusters around 250–500 mcg daily during loading, then lower maintenance use once desired pigmentation is reached.

Community protocols only. Not validated medical dosing.

Safety — what the documented concerns actually are

This section gets its own heading because Melanotan II has one of the more documented safety concern profiles of any peptide on this site.

Not every concern is proven causation. But several are documented enough that they belong in the main article, not hidden in the disclaimer.

Mole changes and new moles

This is the most consistent skin-related concern. Dermatology literature has described changes in existing nevi and new moles appearing in people using Melanotan II. Cardones and Grichnik (2009) documented changes in melanocytic nevi associated with MT-II use.

Melanoma case reports

There are case reports of melanoma being diagnosed during or shortly after Melanotan II use. Causation has not been established. But the signal is documented enough that it should not be dismissed.

Anyone with a personal or family history of melanoma or skin cancer should avoid Melanotan II.

Priapism

Priapism — a prolonged, painful erection — has been reported with Melanotan II use. This is not just an awkward side effect. Priapism can be a medical emergency because prolonged erections can damage tissue if not treated.

Nausea and vomiting

Nausea is one of the most common effects reported with MT-II. This showed up in early human research and is widely reported in community use.

The regulatory situation (April 2026)

Melanotan II is not FDA approved.

The April 2026 FDA Category 2 update included Melanotan II in the group of peptides removed after nominator withdrawal, with Pharmacy Compounding Advisory Committee consultation expected before the end of February 2027.

That does not mean FDA approved Melanotan II. Category 2 removal is not approval. It is not a finding of safety or effectiveness.

FDA and other regulators have historically warned about unregulated Melanotan products, especially because of skin and melanoma-related concerns.

WADA

Melanotan II is not specifically named on the 2026 WADA Prohibited List as a listed compound. But because it is not approved for human therapeutic use, it can fall under the S0 non-approved substances category. That makes it high-risk for WADA-tested athletes.

My read: the regulatory status fits the rest of the story. This is a biologically active compound with real effects, real concern signals, and no approved product pathway.

The purity problem

The standard gray-market peptide concerns apply here. But with Melanotan II, dosing and identity matter even more because the receptor profile is non-selective.

If the vial is underdosed, someone may use more than they think they are using. If the vial is overdosed, they may get more of every effect — not just more tanning. More nausea. More flushing. More blood pressure effect. More sexual arousal effect.

For MT-II, the COA questions are:

Does the COA match the exact batch?
Is identity confirmed by mass spectrometry?
Is purity measured by HPLC?
Is the testing from a real third-party lab?
Are sterility and endotoxin addressed?
Does the vendor avoid health claims?
Is the product clearly labeled as MT-II and not confused with PT-141?

A COA is not decoration. It is the receipt. But with MT-II, even a real COA does not erase the receptor biology or the skin-safety concerns. It only helps answer whether the vial matches the label.

How to read a COA →See our vetted peptide sources →

My read: vendor quality matters, but Melanotan II is not a peptide where quality control solves the whole problem. A clean vial of a higher-risk compound is still a higher-risk compound.

What isn't settled yet

Does Melanotan II cause melanoma, or does it reveal pre-existing risk?
This is not settled. Case reports exist, but causation is not proven.
What is the long-term mole-change profile?
We do not have large, long-term monitored datasets of repeated community-style use.
Is appetite suppression medically meaningful?
The pathway is real, but MT-II is not an approved weight-management drug and the non-selective effect profile makes this a rough tool for that goal.
What are the cardiovascular effects with chronic use?
Blood pressure effects and autonomic symptoms are part of the melanocortin receptor story, but long-term data is limited.
Is non-selective melanocortin activation inherently harder to manage?
My read is yes, conceptually. The more switches a peptide hits, the harder it is to isolate the effect you want from the effects you do not.
What will the PCAC consultation conclude?
The February 2027 FDA process is worth watching, especially given the safety history around MT-II.

Bottom line

My honest read: Melanotan II is one of the most genuinely complicated peptides on this site.

The science is real. The original idea was interesting. The melanocortin biology is legitimate. The tanning effect is documented. A more selective descendant of this research path eventually became an FDA-approved drug.

That is the positive side, and it should not be ignored.

But the concern profile is also real.

Mole changes. New moles. Melanoma case reports. Priapism. Nausea. Blood pressure effects. Those are not imaginary worst-case scenarios invented to scare people. They are documented signals in the literature and in clinical discussion.

The honest position is this:

If the documented skin concerns were absent, Melanotan II would be an interesting research peptide with a non-selective mechanism and thin human evidence.

With the documented skin concerns present, it sits in a different category from most peptides on this site.

That does not mean every user will develop a problem.

It means Melanotan II is the page where the concerns belong front and center, not as a footnote.

Interesting biology. Real tanning effect. Non-selective mechanism. Documented safety signals.

That is the whole picture.

Disclaimer

This page is informational and not medical advice. Biohacking Unlocked is not a medical resource. Melanotan II is not FDA approved for any indication, and research-use products are commonly labeled “for research purposes only / not for human consumption.” Anyone considering peptides should talk with a qualified healthcare provider, especially anyone with a personal or family history of skin cancer, cardiovascular concerns, or medications that affect blood pressure. See our full disclaimer.